BR Biomedical Reports 2049-9434 2049-9442 D.A. Spandidos 10.3892/br.2017.1014 BR-0-0-1014 Articles Mutation analysis of Leber's hereditary optic neuropathy using a multi-gene panel DaiYu 1 * WangChenghui 2 3 * NieZhipeng 2 3 HanJiamin 3 ChenTing 2 ZhaoXiaoxu 2 3 AiCheng 3 JiYanchun 2 GaoTao 1 JiangPingping 2 3 The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China Division of Medical Genetics and Genomics, The Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, P.R. China Institute of Genetics, Zhejiang University, and Department of Genetics, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, P.R. China Correspondence to: Dr Pingping Jiang, Institute of Genetics, Zhejiang University, and Department of Genetics, Zhejiang University School of Medicine, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, P.R. China, E-mail: ppjiang@zju.edu.cn

Contributed equally

 01 2018 08 11 2017 8 1 51 58 10082017 02102017 Copyright © 2018, Spandidos Publications 2018

The present study investigates the spectrum and incidence of mitochondrial DNA (mtDNA) mutations associated with Leber's hereditary optic neuropathy (LHON) in a Han population using a multi-gene panel with 46 LHON-associated mutations among 13 mitochondrial genes. A total of 23 mutations were observed in a cohort of 275 patients and 281 control subjects using multi-gene panel analysis. The causative mutations associated with LHON were identified to be m.11778G>A, m.14484T>C, m.3460 G>A, m.3635G>A, m.3866T>C and m.3733G>A, responsible for 70.55% cases in the patient cohort. The secondary mutations in the Chinese LHON population were m.12811T>C, m.11696 G>A, m.3316G>A, m.3394T>C, m.14502T>C, m.3497C>T, m.3571C>T, m.12338T>C, m.14693A>G, m.4216T>C and m.15951A>G, with incidences of 5.09, 4.36, 4.00, 4.00, 4.00, 2.55, 1.82, 1.82, 1.45, 1.09 and 1.09%, respectively. Besides three hotspot genes, MT-ND1, MT-ND4 and MT-ND6, MT-ND5 also had a high incidence of secondary mutations. Those mutations reported as rare causative mutations in a European LHON population, m.3376G>A, m.3700G>A and m.4171C>A, m.10663T>C, m.13051G>A, m.14482C>G/A, m.14495A>G and m.14568C>T were undetected in the present study. The primary and secondary mutations associated with LHON in the present multi-gene panel will advance the current understanding of the clinical phenotype of LHON, and provide useful information for early diagnosis.

 Leber's hereditary optic neuropathy mitochondrial DNA causative mutation multi-gene panel gene-target sequencing Introduction

Leber's hereditary optic neuropathy (LHON; OMIM 535000) is a classic mitochondrial disease, associated with a rapid, painless, acute or sub-acute bilateral visual loss in young adults, predominantly caused by the primary and secondary mutations in mitochondrial DNA (mtDNA). It has been reported that 1:8,500 individuals harbor a primary LHON-causing mutation and 1:31,000 experience visual loss as a result of LHON in the North East of England (1). Few significant improvements in visual acuity are reported following atrophy of the optic discs. LHON typically affects males more frequently than females, with the incomplete and variable penetrance estimated at ~50% in males and 10% in females (2–4). Additionally, certain LHON cases have additional clinical symptoms, such as movement disorders, dystonia, and multiple-sclerosis-like illness, which complicate the diagnosis in the clinical setting (5–7). Although the majority ofcases of LHON transmitted by maternal inheritance have a history of visual loss in families, up to 40% of cases are sporadic (5).

The genetic cause of LHON is mutations in the mitochondrial genome, which is a double-stranded 16,569-nucleotide pair, circular molecule, consisting of one D-Loop region and 37 genes. The three most causative mutations, m.11778G>A (MT-ND4), m.14484T>C (MT-ND6) and m.3460G>A (MT-ND1), have been reported to account for 90% of LHON patients in a Caucasian population, but for only 38.3 and 46.5% of cases in two large cohorts of Chinese Han subjects with LHON (7–10). Our previous studies have shown the spectrum of genes, MT-ND1, MT-ND4 and MT-ND6, and the frequency of the three primary mutations in a Chinese LHON population (8–10) using Sanger sequencing. In addition, secondary mutations that contributed to the high penetrance, including m.3394T>C (MT-ND1), m.11696G>A (MT-ND4), m.12338T>C (MT-ND5) and m.15951A>G (MT-TT) areusually synergized with m.11778G>A or m.14484T>C or m.3460G>A (11). According to Mitomap (http://www.mitomap.org/), >40 point mutations in mtDNA are associated with LHON, of which the incidence varies between different ethnic backgrounds.

To further understand the spectrum of mutations associated with LHON in a Chinese population, 46 LHON-associated mutations distributed among 13 mitochondrial genes were selected from Mitomap, and multi-gene target sequencing was performed in 275 cases of LHON as well as in 281 Chinese control subjects to distinguish the most frequent mtDNA mutations associated with LHON in the Han population.

 Materials and methods <sec> <title>DNA samples, extraction, quantification and quality control

A total of 275 unrelated LHON samples and 281 Chinese control samples were enrolled from the ophthalmology clinics at Zhejiang University School of Medicine (Hangzhou, China) and Wenzhou Medical College (Wenzhou, China) between 2004 and 2015, as described previously (8–10,12), under protocols approved by Zhejiang University and Wenzhou Medical University Ethics Committees. DNA was extracted from 1 ml peripheral blood using a QIAamp DNA Blood Minikit (51106; Qiagen China Co., Ltd., Shanghai, China). The quality and quantity of DNA were assessed using Qubit 3.0 fluorometers (Thermo Fisher Scientific, Inc., Waltham, MA, USA). DNA samples with concentration >1.0 ng/µl were employed in the sequencing experiments.

 Multi-genepanel design

Multi-gene target sequencing was performed using the VariantPro™ Capture Technology by LC Sciences (Hangzhou, China) as described previously (13). The 46 LHON-associated mutations were selected from Mitomap and previous studies (8–10). As presented in Table I, they were distributed in the following 13 genes: MT-ND1, MT-ND2, MT-ATP6, MT-CO3, MT-ND3, MT-ND4L, MT-ND4, MT-ND5, MT-ND6, MT-CYB, MT-TM, MT-TT and MT-TE. Twenty-seven amplicons that covered all 46 mutations were designed by LC Sciences, as described previously (13). All amplicons were pooled into two polymerase chain reaction (PCR) tubes (tube 1 and tube 2) as VariantPro™ PCR mastermix with an average length of 184 nt (range, 167–203 nt).

 Library preparation and sequencing

Library generation was performed according to the manufacturer's protocol (LC Sciences). Briefly, 5 ng DNA per pool was amplified in 25 cycles of PCR using probe sequences of 27 library amplicons (Table II) and a VariantPro™ PCR mastermix as described previously (13). PCR runs of 18, 20, 24 and 26 cycles were performed to evaluate the influence of the PCR cycles on the experiment. The correlation coefficient, R2, ranged from 0.90–1.00 (average, 0.95), implicating that cycles between 18 and 26 had no influence on the experiment outcome. The amplified products were purified using Agencourt AMPure XP beads [Beckman Coulter (UK) Ltd., High Wycombe, UK]. Each library was diluted to 20 pM and sequenced on an Illumina Miseq with a minimum of 2X 150-bp paired-end reads.

 Data analysis

Low quality reads (reads containing sequencing adaptors or nucleotides with quality scores <20) were removed before alignment. Cleaned, paired-end sequence reads in paired FASTQ files were aligned using Burrows-Wheeler Alignment version 0.1.19 (14). Variant calling was generated using the Genome Analysis Toolkit version 3.3.0 and its Unified Genotyper module (https://www.broadinstitute.org/gatk/guide/tagged?tag=unifiedgenotyper). A Gaussian mixture model was used to evaluate the confidence score for each putative mutation call and novel potential variants. Sequence reads were aligned to the human mtDNA sequence data relative to the revised Cambridge Reference Sequence (GenBank accession no. NC_012920) (15).

 Sanger validation

Thirteen LHON cases associated with m.11778G>A (11) or m.14484T>C (2) mutations and four healthy control samples (available upon request) were selected as the positive and negative controls, respectively, for runs of the panel following validation by Sanger sequencing. Furthermore, 100% correlation was derived from the panel assay and the Sanger sequencing for the positive and negative controls.

 Results <sec> <title>Summary of sequencing data

A total of 118 milion reads were obtained, on average 89% of which were mapped to the amplicon targets and resultedin a mean of 7,001 reads to each sample per amplicon (Table III). The mean reads over the 27 amplicons were distrubed with an average uniformity of coverage of 98.0% (amplicon mean coverage, 20%) and an average read-depth of 1,000 X (Fig. 1). A total of 363 variants were distributed in 46 LHON-associated mutations of all samples.

 Mutations analysis

A total of 363 variants were identified in the cohort of all 556 samples; 285 variants were detected in LHON cases as an average incidence of 104%, whereas only 78 variants were identified in 281 controls with a mean incidence of 28% (Table IV).

As 46 mutations of 13 mitochondrial genes were selected from all populations of the world, variants from LHON cases in the current study were deposited in 8 mitochondrial genes, MT-ND1, MT-CO3, MT-ND4, MT-ND5, MT-ND6, MT-CYB, MT-TT and MT-TE, with frequencies of 16.14, 0.35, 61.40, 6.67, 12.63, 0.35, 1.05 and 1.40%, respectively. Consistent with our previous reports (8–10), MT-ND1, MT-ND4 and MT-ND6 were the hotspots associated with LHON, and almost cover 90% of variants in the present study.

Twenty-three out of the 46 LHON-associated mutations were detected in all subjects. These were as follows: 3316G>A, 3394T>C, 3460G>A, 3497C>T, 3571C>T, 3635G>A, 3733G>A, 3866T>C, 4025C>T and 4216T>C mutations in MT-ND1, 9804G>A in MT-CO3, 11253T>C, 11696G>A and 11778G>A in MT-ND4, m.12338T>C and 12811T>C in MT-ND5, 14325T>C, 14484T>C and 14502T>C in MT-ND6, 14831G>A and 15812G>A in MT-CYB, 15951A>G in MT-TT and 14693A>G in MT-TE. The incidence of these three common mutations m.11778G>A, m.14484T>C and m.3460G>A in this Chinese cohort were 58.90, 9.10 and 0.73%, respectively. In addition, two causative mutations were detected; m.3635G>A in 1 patient and m.3866T>C in 4 patients (one case carrying both m.11778G>A and m.3866T>C mutations), as reported previously (16). Notably, three mutations, m.3733G>A, m.4025C>T and m.11253T>C, were observed in one LHON case each, but absent in the control cohort. Whereas, m.4025C>T and m.11253T>C were observed in the control population in our recent studies (8,9).

Thirteen secondary mutations were identified in 30.55% patients. The incidence of these known secondary mutations, m.12811T>C, m.11696G>A, m.3316G>A, m.3394T>C, m.14502T>C, m.3497C>T, m.3571C>T, m.12338T>C, m.14693A>G, m.4216T>C, m.15951A>G, m.14831G>A and m.9804G>A were 5.09, 4.36, 4.00, 4.00, 4.00, 2.55, 1.82, 1.82, 1.45, 1.09, 1.09, 0.36 and 0.36%, respectively. A total of 88 variations from these 13 mutations were observed in patients. Among these, 67 variations were concurrent with either m.11778G>A (59 variations, except 1 from the m.3866T>C mutation) or m.14484T>C (8 variations). Besides the hotspots of MT-ND1, MT-ND4 and MT-ND6, the MT-ND5 gene was frequently accumulated in the distribution of secondary mutations with an incidence of 6.91% in the patients. In addition, the incidence of MT-ND1, MT-ND4 and MT-ND6 for secondary mutations, were 13.45, 4.36 and 4%, respectively. The secondary mutations were predominantly present in the patient and control populations. Of those, mutations m.12338T>C m.4216T>C, m.3571C>T and m.14831 G>A had higher incidences in the control cohort than in the patients. Two LHON-associated mutations (m.14325T>C and m.15812G>A) only arose in the control population in the present study.

 Discussion

The present study evaluated the distribution of mitochondrial genes and mutations among 275 Chinese LHON patients, in parallel with a control cohort of 281 subjects, using a multi-gene panel. Mutations of the multi-gene panel were designed from the Mitomap database, previous reports and our previous study in a Chinese Han population (8–10). Twenty-seven amplicons, the specific primers for the point mutations, covered those of 46 mutations, as well as other substitutions in the amplicons, such as pathogenic mutations, m.3697G>A, m.10197G>A and m.14459G>A in the fragments of amplicon 4, 13 and 23, respectively. None of these three rare causative mutations were recorded among subjects in the test. Of the 46 mutations, the m.14727T>C variant in the MT-TE gene reported in encephalomyopathy patients (17), was set as a negative control variant in the panel and was absent in all of the subjects. The panel with high-throughput sequencing makes it possible to screen multi-genes or multi-single nucleotide polymorphisms (SNPs) for subjects in a run, and provide more information than traditional Sanger sequencing. Certainly, sequencing the whole mtDNA genome is an optional selection using next generation sequencing. The information from the primary and secondary mutations may be indicative regarding the incomplete penetrance and other clinical symptoms.

It is generally accepted that LHON-associated mutations and their incidence are varied in populations with different ethnic backgrounds (18). Consistent results were confirmed in our multi-gene panel screening. Twenty-three mutations in the panels were absent in the patients and control cohort in the current study. Those mutations reported as rare causative mutations in a European LHON population, m.3376G>A, m.3700G>A and m.4171C>A in the MT-ND1 gene (19–21), m.10663T>C in the MT-ND4L (20), m.13051G>A in the MT-ND5 gene (22), m.14482C>G/A, m.14495A>G and m.14568C>T in the MT-ND6 gene (8,20,23), were undetected in the present study. However, 6 causative mutations, m.11778G>A, m.14484T>C, m.3460G>A, m.3635G>A, m.3866T>C and m.3733G>A were observed in 194 LHON cases with their contribution of 83.51, 12.89, 1.04, 0.52, 2.06 and 0.52. Of these, the incidence of m.3460G>A was markedly lower in this cohort than that in a Caucasian population reported by Mackey et al (24). Additionally, the spectrum of secondary mutations associated with LHON was also dependent on their ethnic background, and were distinct between the Chinese and Caucasian cohorts. This panel screening demonstrated that the secondary mutations, m.12811T>C, m.11696G>A, m.3394T>C, m.3316G>A, m.14502T>C and m.12338T>C had higher frequencies in the patient cohort, as these mutations were assigned to Asian mtDNA lineage, including the macro-haplo group of M and N. Certainly, m.12811T>C is considered to be a polymorphic variant in sub-haplo groups of M7. While, mutations, m.3394T>C and m.11696G>A are categorized as haplo group-specific variants of M9a and D4j, respectively (25,26). Congruent results were obtained in our previous reports (27).

Usually, secondary mutations, proposed to increase the penetrance of LHON (25–27), are observed in LHON cases associated with m.11778G>A or m.14484T>C mutations. In the present study, 77.27% of variations of secondary mutations were coexistent with one of the primary mutations, m.11778G>A and m.14484T>C. Their detailed distribution was illustrated in Table V. Secondary mutations m.12811T>C, m.11696G>A, m.14502T>C, m.3394T>C and m.3316G>A exhibited the most co-occurrence with m.11778G>A. Meanwhile, three LHON cases carried m.14484T>C and m.14502T>C together. Notably, the m.14502T>C mutation was evidenced as a modifier in the phenotypic manifestation of LHON (28), although it was reported as a causative mutation elsewhere (https://www.mitomap.org/foswiki). Furthermore, more than one secondary mutation co-occurred with m.11778G>A, but not with m.14484T>C in this panel. m.3497C>T and m.3571C>T, which belong to the haplo group variants of B4c1, arose in three cases associated with m.11778G>A. In addition, m.9804G>A and m.14831G>A, reported as LHON-associated mutations in Caucasian cases, were common in the present control cohort according to the panel analysis. It was confirmed that the spectrum of mutations varied between ethnic backgrounds and indicated that the selected SNPs of the panel would be optimized for a Han population in the future.

In conclusion, the current data indicates that the spectrum and incidence of mtDNA mutation-associated LHON cases in the Han population are different to those in a Caucasian population. Here, the causative mutations associated with LHON, m.11778G>A, m.14484T>C, m.3460G>A, m.3635G>A, m.3866T>C and m.3733G>A, were observed in 70.55% of the patient cohort. The common secondary mutations in the Chinese LHON population were m.12811T>C, m.11696G>A, m.3394T>C, m.3316G>A, m.14502T>C and m.12338T>C. Furthermore, besides the three hotspots genes MT-ND1, MT-ND4 and MT-ND6, MT-ND5 also had a high incidence of secondary mutations including m.12811T>C and m.12338T>C; this finding was comparable with a previous study (29). The primary and secondary mutation-associated LHON cases in the present multi-gene panel will advance current understanding of the clinical phenotype of LHON, and offer valuable information for the early diagnosis and subsequent options of intervention for mitigating risk of additional vision loss in LHON patients.

 Acknowledgements

The present study was supported by the National Technologies R&D Program (grant no. 2012BAI09B03) and a grant from the National Natural Science Foundation of China (grant no. 31671303).

 Abbreviations LHON

Leber's hereditary optic neuropathy

 mtDNA

mitochondrial DNA

 References Y-W-ManPGriffithsPGBrownDTHowellNTurnbullDMChinneryPFThe epidemiology of Leber hereditary optic neuropathy in the North East of EnglandAm J Hum Genet72333339200310.1086/34606612518276 SaracchiEDifrancescoJCBrighinaLMarzoratiLCurtòNALampertiCCarraraFZevianiMFerrareseCA case of Leber hereditary optic neuropathy plus dystonia caused by G14459A mitochondrial mutationNeurol Sci34407408201310.1007/s10072-012-1013-122426787 HowellNMackeyDALow-penetrance branches in matrilineal pedigrees with Leber hereditary optic neuropathyAm J Hum Genet6312201224199810.1086/3020499867707 FraserJABiousseVNewmanNJThe neuro-ophthalmology of mitochondrial diseaseSurv Ophthalmol55299334201010.1016/j.survophthal.2009.10.00220471050 Yu-Wai-ManPGriffithsPGChinneryPFMitochondrial optic neuropathies – disease mechanisms and therapeutic strategiesProg Retin Eye Res3081114201110.1016/j.preteyeres.2010.11.00221112411 KimSHKimJSLeber's ‘Plus’ in a Korean patient with 14484/ND6 mutationJ Clin Neurol12512514201610.3988/jcn.2016.12.4.51227486939 JiaXLiSXiaoXGuoXZhangQMolecular epidemiology of mtDNA mutations in 903 Chinese families suspected with Leber hereditary optic neuropathyJ Hum Genet51851856200610.1007/s10038-006-0032-216972023 JiYLiangMZhangJZhuLZhangZFuRLiuXZhangMFuQZhaoFMitochondrial ND1 variants in 1281 Chinese subjects with Leber's hereditary optic neuropathyInvest Ophthalmol Vis Sci5723772389201610.1167/iovs.16-1924327177320 JiangPLiangMZhangJGaoYHeZYuHZhaoFJiYLiuXZhangMPrevalence of mitochondrial ND4 mutations in 1281 Han Chinese subjects with Leber's hereditary optic neuropathyInvest Ophthalmol Vis Sci5647784788201510.1167/iovs.14-1615826218905 LiangMJiangPLiFZhangJJiYHeYXuMZhuJMengXZhaoFFrequency and spectrum of mitochondrial ND6 mutations in 1218 Han Chinese subjects with Leber's hereditary optic neuropathyInvest Ophthalmol Vis Sci5513211331201410.1167/iovs.13-1301124398099 Yu-Wai-ManPChinneryPFLeber hereditary optic neuropathyGeneReviews® [Internet]PagonRAAdamMPArdingerHHWallaceSEAmemiyaABeanLJHBirdTDFongCTMeffordHCSmithRJHUniversity of WashingtonSeattle, WA19932016 QuJLiRZhouXTongYLuFQianYHuYMoJQWestCEGuanMXThe novel A4435G mutation in the mitochondrial tRNAMet may modulate the phenotypic expression of the LHON-associated ND4 G11778A mutationInvest Ophthalmol Vis Sci47475483200610.1167/iovs.05-0665 LiXLiuLXiQZhaoXFangMMaJZhuZWangXShiCWangJShort-term serum deprivation causes no significant mitochondrial DNA mutation in vascular smooth muscle cells revealed by a new next generation sequencing technologyActa Biochim Biophys Sin (Shanghai)48862864201610.1093/abbs/gmw059 LiHDurbinRFast and accurate short read alignment with Burrows-Wheeler transformBioinformatics2517541760200910.1093/bioinformatics/btp324 AndrewsRMKubackaIChinneryPFLightowlersRNTurnbullDMHowellNReanalysis and revision of the Cambridge reference sequence for human mitochondrial DNANat Genet23147199910.1038/13779 ZhouXQianYZhangJTongYJiangPLiangMDaiXZhouHZhaoFJiYLeber's hereditary optic neuropathy is associated with the T3866C mutation in mitochondrial ND1 gene in three Han Chinese familiesInvest Ophthalmol Vis Sci5345864594201210.1167/iovs.11-9109 TruongHTNguyenVANguyenLVPhamVAPhanTNScreening of common point-mutations and discovery of new T14727C change in mitochondrial genome of Vietnamese encephalomyopathy patientsMitochondrial DNA A DNA Mapp Seq Anal27441448201610.3109/19401736.2014.900665 WallaceDCLottMTLeber hereditary optic neuropathy: Exemplar of an mtDNA diseaseHandb Exp Pharmacol240339376201710.1007/164_2017_2 BlakelyELde SilvaRKingASchwarzerVHarrowerTDawidekGTurnbullDMTaylorRWLHON/MELAS overlap syndrome associated with a mitochondrial MTND1 gene mutationEur J Hum Genet13623627200510.1038/sj.ejhg.5201363 AchilliAIommariniLOlivieriAPalaMKashaniB HooshiarReynierPLa MorgiaCValentinoMLLiguoriRPizzaFRare primary mitochondrial DNA mutations and probable synergistic variants in Leber's hereditary optic neuropathyPLoS One7e42242201210.1371/journal.pone.0042242 KimJYHwangJMParkSSMitochondrial DNA C4171A/ND1 is a novel primary causative mutation of Leber's hereditary optic neuropathy with a good prognosisAnn Neurol51630634200210.1002/ana.10177 FauserSLeo-KottlerBBeschDLuberichsJConfirmation of the 14568 mutation in the mitochondrial ND6 gene as causative in Leber's hereditary optic neuropathyOphthalmic Genet23191197200210.1076/opge.23.3.191.7881 ChinneryPFBrownDTAndrewsRMSingh-KlerRRiordan-EvaPLindleyJApplegarthDATurnbullDMHowellNThe mitochondrial ND6 gene is a hot spot for mutations that cause Leber's hereditary optic neuropathyBrain124209218200110.1093/brain/124.1.209 MackeyDAOostraRJRosenbergTNikoskelainenEBronte-StewartJPoultonJHardingAEGovanGBolhuisPANorbySPrimary pathogenic mtDNA mutations in multigeneration pedigrees with Leber hereditary optic neuropathyAm J Hum Genet594814851996 ZhangMZhouXLiCZhaoFZhangJYuanMSunYHWangJTongYLiangMMitochondrial haplogroup M9a specific variant ND1 T3394C may have a modifying role in the phenotypic expression of the LHON-associated ND4 G11778A mutationMol Genet Metab101192199201010.1016/j.ymgme.2010.07.014 QuJLiRZhouXTongYYangLChenJZhaoFLuCQianYLuFGuanMXCosegregation of the ND4 G11696A mutation with the LHON-associated ND4 G11778A mutation in a four generation Chinese familyMitochondrion7140146200710.1016/j.mito.2006.11.015 SudoyoHSuryadiHLertritPPramoonjagoPLyrawatiDMarzukiSAsian-specific mtDNA backgrounds associated with the primary G11778A mutation of Leber's hereditary optic neuropathyJ Hum Genet47594604200210.1007/s100380200091 JiangPLiangMZhangCZhaoXHeQCuiLLiuXSunYHFuQJiYBiochemical evidence for a mitochondrial genetic modifier in the phenotypic manifestation of Leber's hereditary optic neuropathy-associated mitochondrial DNA mutationHum Mol Genet2536133625201610.1093/hmg/ddv498 SeongMWChoiJParkSSKimJYHwangJMNovel MT-ND5 gene mutation identified in Leber's hereditary optic neuropathy patient using mitochondrial genome sequencingJ Neurol Sci375301303201710.1016/j.jns.2017.01.064

Mean coverage of 27 amplicons. Upper: Average read coverages (log 10) for each amplicon (556 samples). Lower: Read coverages (log10) for each amplicon from one sample.

Mutations in the multi-gene panel (n=46).

Index Gene name Var start Var end Ref allele Var allele Amino acid change
  1 MT-ND1 3316 3316 G A A-T
  2 MT-ND1 3376 3376 G A E-K
  3 MT-ND1 3394 3394 T C Y-H
  4 MT-ND1 3460 3460 G A A-T
  5 MT-ND1 3497 3497 C T A-V
  6 MT-ND1 3571 3571 C T L-F
  7 MT-ND1 3635 3635 G A S-N
  8 MT-ND1 3700 3700 G A A-T
  9 MT-ND1 3733 3733 G A E-K
10 MT-ND1 3866 3866 T C I-T
11 MT-ND1 4025 4025 C T T-M
12 MT-ND1 4171 4171 C A L-M
13 MT-ND1 4216 4216 T C Y-H
14 MT-ND2 4640 4640 C A I-M
15 MT-ND2 5244 5244 G A G-S
16 MT-ATP6 9101 9101 T C I-T
17 MT-CO3 9804 9804 G A A-T
18 MT-ND3 10237 10237 T C I-T
19 MT-ND4L 10663 10663 T C V-A
20 MT-ND4L 10680 10680 G A A-T
21 MT-ND4 11253 11253 T C I-T
22 MT-ND4 11696 11696 G A V–I
23 MT-ND4 11778 11778 G A R-H
24 MT-ND5 12338 12338 T C M-T
25 MT-ND5 12811 12811 T C Y-H
26 MT-ND5 12848 12848 C T A-V
27 MT-ND5 13051 13051 G A G-S
28 MT-ND5 13528 13528 A G T-A
29 MT-ND5 13637 13637 A G Q-R
30 MT-ND5 13730 13730 G A G-E
31 MT-ND6 14279 14279 G A S-L
32 MT-ND6 14325 14325 T C N-D
33 MT-ND6 14482 14482 C A M-I
34 MT-ND6 14482 14482 C G M-I
35 MT-ND6 14484 14484 T C M-V
36 MT-ND6 14495 14495 A G L-S
37 MT-ND6 14498 14498 T C Y-C
38 MT-ND6 14502 14502 T C I–V
39 MT-ND6 14568 14568 C T G-S
40 MT-ND6 14596 14596 A T I-M
41 MT-CYB 14831 14831 G A A-T
42 MT-CYB 15812 15812 G A V-M
43 MT-TM 4435 4435 A G tRNAMet
44 MT-TT 15951 15951 A G tRNAThr
45 MT-TE 14693 14693 A G tRNAGlu
46 MT-TE 14727 14727 T C tRNAGlu

Var start, start site of variant; var end, end site of variant; ref allele, referenced allele; Var allele, variant allele.

PCR amplicons.

Index Gene name Tgt start Tgt end Prb strand Prb start Prb end Var start Var end Prb length (bp) Amp length (bp)
1 MT-ND1 3,316 3,866 − 3,269 3,439 3,288 3,425 171 303
2 MT-ND1 3,316 3,866 + 3,402 3,585 3,415 3,571 184 316
3 MT-ND1 3,316 3,866 − 3,526 3,699 3,543 3,684 174 306
4 MT-ND1 3,316 3,866 + 3,643 3,812 3,661 3,794 170 302
5 MT-ND1 3,316 3,866 − 3,745 3,936 3,767 3,918 192 324
6 MT-ND1 4,025 4,025 − 3,952 4,140 3,962 4,126 189 321
7 MT-ND1 4,171 4,216 + 4,132 4,334 4,145 4,315 203 335
8 MT-TM 4,435 4,435 − 4,363 4,529 4,380 4,514 167 299
9 MT-ND2 4,640 4,640 − 4,482 4,667 4,494 4,655 186 318
10 MT-ND2 5,244 5,244 + 5,140 5,317 5,154 5,302 178 310
11 MT-ATP6 9,101 9,101 − 9,026 9,223 9,041 9,208 198 330
12 MT-CO3 9,804 9,804 − 9,639 9,839 9,653 9,824 201 333
13 MT-ND3 10,237 10,237 − 10,161 10,331 10,178 10,310 171 303
14 MT-ND4L 10,663 10,680 − 10,541 10,710 10,560 10,692 170 302
15 MT-ND4 11,253 11,253 + 11,226 11,404 11,239 11,386 179 311
16 MT-ND4 11,696 11,778 + 11,642 11,833 11,660 11,813 192 324
17 MT-ND5 12,338 12,338 − 12,213 12,399 12,230 12,385 187 319
18 MT-ND5 12,811 12,848 + 12,764 12,941 12,776 12,924 178 310
19 MT-ND5 13,051 13,051 − 12,967 13,146 12,984 13,128 180 312
20 MT-ND5 13,528 13,730 + 13,488 13,682 13,503 13,665 195 327
21 MT-ND5 13,528 13,730 + 13,577 13,774 13,590 13,760 198 330
22 MT-ND6 14,279 14,325 − 14,251 14,421 14,267 14,408 171 303
23 MT-TE; MT-ND6; MT-CYB 14,482 14,831 + 14,444 14,645 14,460 14,628 202 334
24 MT-TE; MT-ND6; MT-CYB 14,482 14,831 − 14,587 14,762 14,610 14,748 176 308
25 MT-TE; MT-ND6; MT-CYB 14,482 14,831 + 14,699 14,866 14,720 14,857 168 300
26 MT-CYB; MT-TT 15,812 15,951 + 15,780 15,966 15,801 15,945 187 319
27 MT-CYB; MT-TT 15,812 15,951 − 15,792 15,989 15,809 15,974 198 330

PCR, polymerase chain reaction; Tgt, target; prb, probe; var, variation; +, forward primer; -, antisense primer.

Summary of sequencing data in the panel for 556 samples.

Variable Outcome
Total no. of reads 118,156,518
Reads mapped to the amplicons (forward primer) 110,440,487
Reads mapped to the amplicons (reverse primer) 108,812,285
Reads mapped to the amplicon targets 105,107,193
Reads mapped to each amplicon (average) 3,892,859
Reads mapped to each sample per amplicon (mean) 7,001.5
Reads enrichment to the targets,% (average) 89
Uniformity of coverage, % (20% mean) 98
Total no. of variants among 46 point mutations 363

Summary information of 46-point mutations in the cohort.

Primer mutations Incidence (%)
Indexa Gene SNP Total variants Patients (n=275) 11778 14484 3460 Controls (n=281) Patients Controls
1 MT-ND1 3316G>A 15 11 7 1 0 4 4.00 1.42
2 3376G>A 0 0 0 0 0 0 0.00 0.00
3 3394T>C 19 11 7 0 0 8 4.00 2.85
4 3460G>A 2 2 0 0 2 0 0.73 0.00
5 3497C>T 14 7 4 0 0 7 2.55 2.50
6 3571C>T 11 5 3 0 0 6 1.82 2.14
7 3635G>A 1 1 0 0 0 0 0.36 0.00
8 3700G>A 0 0 0 0 0 0 0.00 0.00
9 3733G>A 1 1 0 0 0 0 0.36 0.00
10 3866T>C 4 4 1 0 0 0 1.45 0.00
11 4025C>T 1 1 0 0 0 0 0.36 0.00
12 4171C>A 0 0 0 0 0 0 0.00 0.00
13 4216T>C 11 3 0 0 0 8 1.09 2.85
14 MT-ND2 4640C>A 0 0 0 0 0 0 0.00 0.00
15 5244G>A 0 0 0 0 0 0 0.00 0.00
16 MT-ATP6 9101T>C 0 0 0 0 0 0 0.00 0.00
17 MT-CO3 9804G>A 2 1 1 0 0 1 0.36 0.36
18 MT-ND3 10237T>C 0 0 0 0 0 0 0.00 0.00
19 MT-ND4L 10663T>C 0 0 0 0 0 0 0.00 0.00
20 10680G>A 0 0 0 0 0 0 0.00 0.00
21 MT-ND4 11253T>C 1 1 1 0 0 0 0.36 0.00
22 11696G>A 18 12 10 1 0 6 4.36 2.14
23 11778G>A 162 162 162 0 0 0 58.90 0.00
24 MT-ND5 12338T>C 19 5 2 0 0 14 1.82 4.98
25 12811T>C 21 14 12 0 0 7 5.09 2.49
26 12848C>T 0 0 0 0 0 0 0.00 0.00
27 13051G>A 0 0 0 0 0 0 0.00 0.00
28 13528A>G 0 0 0 0 0 0 0.00 0.00
29 13637A>G 0 0 0 0 0 0 0.00 0.00
30 13730G>A 0 0 0 0 0 0 0.00 0.00
31 MT-ND6 14279G>A 0 0 0 0 0 0 0.00 0.00
32 14325T>C 2 0 0 0 0 2 0.00 0.71
33 14482C>A 0 0 0 0 0 0 0.00 0.00
34 14482C>G 0 0 0 0 0 0 0.00 0.00
35 14484T>C 25 25 0 25 0 0 9.10 0.00
36 14495A>G 0 0 0 0 0 0 0.00 0.00
37 14498T>C 0 0 0 0 0 0 0.00 0.00
38 14502T>C 18 11 8 3 0 7 4.00 2.49
39 14568C>T 0 0 0 0 0 0 0.00 0.00
40 14596A>T 0 0 0 0 0 0 0.00 0.00
41 MT-CYB 14831G>A 5 1 0 0 0 4 0.36 1.42
42 15812G>A 1 0 0 0 0 1 0.00 0.36
43 MT-TM 4435A>G 0 0 0 0 0 0 0.00 0.00
44 MT-TT 15951A>G 5 3 1 2 0 2 1.09 0.71
45 MT-TE 14693A>G 5 4 3 1 0 1 1.45 0.36
46 14727T>C 0 0 0 0 0 0 0.00 0.00
Total 162b 25c
variants 363 285 (60) (8) 2 78 103.64 27.76

The index number is according to Table I

162 subjects carrying the m.11778G>A mutation, of which 60 subjects were carrying the m.11778G>A and one of the secondary variants

25 subjects carrying the m.14484T>C mutation, of which 8 subjects were carrying the m.14484T>C and a secondary variant. The three common mutations for LHON are emboldened. SNP, single nucleotide polymorphism.

Distribution of secondary mutations with m.11778 G>A and m.14484 T>C.

Secondary mutation (cases harboring successive secondary mutations, n)
Primary mutation 1 2 3 Samples, n
12811T>C − − 12
11696G>A 3394 T>C (1) − 10
14502T>C 14693 A>G (1) 9804 G>A (1) 8
3866 T>C (1) −
3316G>A − − 7
11778 G>A 3394T>C 11696 G>A (1) − 7
3497C>T 3571 C>T (3) − 4
14693A>G 14502 T>C (1) − 3
3571C>T 3497 C>T (3) − 3
12338T>C − − 2
9804G>A 14502 T>C (1) 14693 A>G (1) 1
11253T>C − − 1
15951A>G − − 1
14484 T>C 14502T>C − − 3
15951A>G − − 2
11696G>A − − 1
3316G>A − − 1
14693A>G − − 1